Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
Davendra P. S. Sohal et al.
JAMA ONCOLOGY (2021)
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
Volker Kunzmann et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Nguyen H. Tran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer
Susan Tsai et al.
ANNALS OF SURGERY (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Global, regional and national burden of pancreatic cancer, 1990 to 2017: Results from the Global Burden of Disease Study 2017
Xiang Chen et al.
PANCREATOLOGY (2020)
Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis
Mao Ye et al.
HPB (2020)
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
Adam R. Wolfe et al.
CANCER MEDICINE (2020)
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Jordan M. Cloyd et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Adjuvant and neoadjuvant therapy for breast cancer
Tadahiko Shien et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
Vincent P. Groot et al.
ANNALS OF SURGERY (2019)
Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer
Savio G. Barreto et al.
ANZ JOURNAL OF SURGERY (2019)
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
Fuyuhiko Motoi et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy
Ammar A. Javed et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2019)
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
Yoshihiro Miyasaka et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients
Shuichi Aoki et al.
BMC CANCER (2019)
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
Ganji Purnachandra Nagaraju et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
Michiaki Unno et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma A Propensity Score Adjusted Analysis
Jordan M. Cloyd et al.
PANCREAS (2019)
Final results of JASPAC05: Phase II trial of neoadjuvant S-1 and concurrent radiotherapy followed by surgery in borderline resectable pancreatic cancer.
Shinichiro Takahashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
Margaret A. Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX
Timothy J. Vreeland et al.
PANCREAS (2019)
Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery
Chad A. Barnes et al.
SURGERY (2019)
The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
Zhi-Qiang Wang et al.
CANCER COMMUNICATIONS (2019)
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma
Hidetoshi Eguchi et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Kyle C. Cuneo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer
Xifeng Xu et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2019)
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Benedikt Kaufmann et al.
DIGESTIVE SURGERY (2019)
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
Xiang Li et al.
ONCOLOGIST (2019)
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Alison Bradley et al.
SCIENTIFIC REPORTS (2019)
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer
Jennifer Y. Wo et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy
Eran van Veldhuisen et al.
HPB (2018)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2018)
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma
Michele Reni et al.
EUROPEAN JOURNAL OF CANCER (2018)
R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy
Hirofumi Kamachi et al.
IN VIVO (2018)
Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
Javed Mahmood et al.
CANCERS (2018)
Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
Pascal Hammel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost- intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer
Eun Sang Oh et al.
RADIATION ONCOLOGY JOURNAL (2018)
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial
Michele Reni et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting
Tsutomu Fujii et al.
JOURNAL OF GASTROENTEROLOGY (2017)
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma
Benedetto Ielpo et al.
SURGICAL ONCOLOGY-OXFORD (2017)
Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
Hyeong Seok Kim et al.
ANNALS OF SURGICAL TREATMENT AND RESEARCH (2017)
Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies
Han-Xiang Zhan et al.
CANCER MEDICINE (2017)
Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population
Xiang Li et al.
CANCER LETTERS (2017)
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
Florence Huguet et al.
TARGETED ONCOLOGY (2016)
Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients
Thilo Hackert et al.
ANNALS OF SURGERY (2016)
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey M. Stein et al.
BRITISH JOURNAL OF CANCER (2016)
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
Michele Reni et al.
BRITISH JOURNAL OF CANCER (2016)
Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial
Ken-Ichi Okada et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer
Jennifer L. Williams et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2016)
Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study
John R. Bergquist et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)
Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer
Awalpreet S. Chadha et al.
SEMINARS IN RADIATION ONCOLOGY (2016)
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors
Toshihiko Masui et al.
SURGERY TODAY (2016)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Matthew H. G. Katz et al.
JAMA SURGERY (2016)
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma
Eric A. Mellon et al.
ACTA ONCOLOGICA (2015)
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
Eran Sadot et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience
Ulrich Nitsche et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials
Taro Kishi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
Riccardo Casadei et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2015)
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer
Mohammed Aldakkak et al.
HPB (2015)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen et al.
NATURE COMMUNICATIONS (2015)
Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
Marlo Blazer et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
L. Marthey et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Henriette Golcher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2015)
A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Eileen M. O'Reilly et al.
ANNALS OF SURGERY (2014)
Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
J. Bart Rose et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival
Ching-Wei D. Tzeng et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2014)
Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association
Mahmoud M. Al-Hawary et al.
RADIOLOGY (2014)
Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma
George Van Buren et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
Edward J. Kim et al.
CANCER (2013)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Philippe Rougier et al.
EUROPEAN JOURNAL OF CANCER (2013)
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
Brian A. Boone et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Terence M. Williams et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
Manish Patel et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prospective phase II trial of Neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head
Stefan Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
Douglas B. Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma
MS Talamonti et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Preoperative versus postoperative chemoradiotherapy for rectal cancer
R Sauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
